Kancera — Investor Relations & Filings

Novakand Pharma AB, formerly Kancera AB, is a pharmaceutical company that was focused on the development of small molecule therapeutics. Its primary research areas included cancer and inflammatory diseases. The company's pipeline featured drug candidates targeting the fractalkine system for cardiovascular and inflammatory conditions, as well as ROR inhibitors for oncology applications such as leukemia and solid tumors. Following a strategic review prompted by challenging capital market conditions, the company has initiated a process to seek a reverse takeover, aiming to leverage its public listing and cash assets for a merger with another entity.